Virtus Logo


We offer a range of in vitro and in vivo pre-clinical models to complement our clinical trial expertise.

In Vivo

Our team has been involved in the development of a range of animal models of respiratory disease which are offered to provide proof of concept and proof of mechanism of small molecules, biologics and vaccines.

Mouse models


  • Human rhinovirus, RSV and influenza virus infection
  • Streptococcus pneumoniae infection


Chronic airway disease

  • House dust mite and ovalbumin asthma models
  • Elastase/LPS COPD model


Viral exacerbations

  • Rhinovirus-induced exacerbation of asthma
  • Rhinovirus-induced exacerbation of COPD


In Vitro

We have extensive experience using in vitro models of cell biology and infection to deliver insights into mechanisms of respiratory disease and therapy efficacy and mechanism of action.

We offer a range of cell types and pathogens including:

Cell Types

Bronchial epithelial cells

  • Cell lines e.g. A549, BEAS-2B, H292
  • Primary bronchial epithelial cells from donors of various ages and disease status including healthy subjects, smokers, asthmatics and COPD
  • Submerged cultures
  • Air liquid interface (ALI) cultures


Monocytes/macrophages/dendritic cells

  • Isolated primary cells (PBMC or BAL derived)
  • THP-1 cells
  • Monocyte-derived M0, M1 and M2 polarised macrophages



  • Primary T cells (PBMC or tonsil derived)


Infectious agents


  • Human rhinovirus (RV)
  • Respiratory Syncytial Virus (RSV)
  • Influenza A



  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Moraxella catarrhalis


Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.


Our research has been published in high profile journals and presented at several international conferences.

Read the abstracts

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong